{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-083386","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.174324+00:00","generated_at":"2026-05-31T20:50:16.254810+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lexeo positive Phase 1/2 data for LX2006 in FA cardio: LVMI -11.4% at 12mo, safe","bullets":["Mean LVMI reduction 11.4% at 12 months and 18.3% at 18 months in patients with elevated baseline LVMI.","75% of elevated-baseline patients achieved >10% LVMI reduction at 12 months.","hsTnI, a myocardial injury biomarker, reduced 53.3% on average at 12 months (n=5).","Frataxin expression increased post-treatment in all evaluable biopsies; no treatment-related SAEs.","Cohort 3 dosing started (1.2x10^12 vg/kg); DSMB endorsed progression; 13 total participants dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-083386","json":"https://secwatch.observer/filing/0000950170-24-083386.json","markdown":"https://secwatch.observer/filing/0000950170-24-083386.md","text":"https://secwatch.observer/filing/0000950170-24-083386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024083386/0000950170-24-083386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024083386/lxeo-20240715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:50:16.254810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}